These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 10417495)

  • 81. Inhibition of dextromethorphan metabolism by moclobemide.
    Härtter S; Dingemanse J; Baier D; Ziegler G; Hiemke C
    Psychopharmacology (Berl); 1998 Jan; 135(1):22-6. PubMed ID: 9489930
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Moclobemide effects on prolactin plasma levels in healthy individuals: the hormonal increase induced by a single dose is maintained during a 4-week period of drug intake.
    Juruena MF; Pires ML; Calil HM
    Int Clin Psychopharmacol; 1997 Nov; 12(6):317-21. PubMed ID: 9547133
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group.
    Ahrens SP; Farmer MV; Williams DL; Willoughby E; Jiang K; Block GA; Visser WH
    Cephalalgia; 1999 Jun; 19(5):525-30. PubMed ID: 10403069
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine.
    Gieschke R; Schmid-Burgk W; Amrein R
    J Neural Transm Suppl; 1988; 26():97-104. PubMed ID: 3283292
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Efficacy of 5HT in migraine.
    Buzzi MG
    Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
    [No Abstract]   [Full Text] [Related]  

  • 86. [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance].
    Ikemoto F; Toru T; Aijima H; Natsumeda Y
    Nihon Yakurigaku Zasshi; 2004 Apr; 123(4):295-302. PubMed ID: 15056946
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity.
    Gleiter CH; Nilsson E; Mühlbauer B; Antonin KH; Bieck PR
    J Neural Transm Gen Sect; 1992; 89(1-2):129-33. PubMed ID: 1418864
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Biochemistry and pharmacology of moclobemide, a prototype RIMA.
    Haefely W; Burkard WP; Cesura AM; Kettler R; Lorez HP; Martin JR; Richards JG; Scherschlicht R; Da Prada M
    Psychopharmacology (Berl); 1992; 106 Suppl():S6-14. PubMed ID: 1546143
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide.
    Guentert TW; Schmitt M; Dingemanse J; Banken L; Jonkman JH; Oosterhuis B
    Drug Metabol Drug Interact; 1992; 10(4):307-22. PubMed ID: 1304448
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.
    Cusson JR; Goldenberg E; Larochelle P
    J Clin Pharmacol; 1991 May; 31(5):462-7. PubMed ID: 2050833
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers.
    Yates R; Nairn K; Dixon R; Kemp JV; Dane AL
    J Clin Pharmacol; 2002 Nov; 42(11):1244-50. PubMed ID: 12412823
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor.
    Korn A; Da Prada M; Raffesberg W; Allen S; Gasic S
    J Neural Transm Suppl; 1988; 26():57-71. PubMed ID: 3162952
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers.
    Audebert C; Blin O; Monjanel-Mouterde S; Auquier P; Pedarriosse AM; Dingemanse J; Durand A; Cano JP
    Eur J Clin Pharmacol; 1992; 43(5):507-12. PubMed ID: 1483487
    [TBL] [Abstract][Full Text] [Related]  

  • 94. 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.
    Ferrari MD
    Neurology; 1997 Mar; 48(3 Suppl 3):S21-4. PubMed ID: 9071266
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Potentiation of the pressor effect of intravenously administered tyramine during moclobemide treatment.
    Zimmer R; Fischbach R; Breuel HP
    Acta Psychiatr Scand Suppl; 1990; 360():76-7. PubMed ID: 2248082
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A cross-study comparison of the effects of moclobemide and brofaromine on actual driving performance and estimated sleep.
    Ramaekers JG; van Veggel LM; O'Hanlon JF
    Clin Neuropharmacol; 1994; 17 Suppl 1():S9-18. PubMed ID: 7954488
    [TBL] [Abstract][Full Text] [Related]  

  • 97. On the reversibility of reversible MAO inhibitors.
    Waldmeier PC
    Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):305-10. PubMed ID: 4022138
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome".
    Dingemanse J; Wallnöfer A; Gieschke R; Guentert T; Amrein R
    Clin Pharmacol Ther; 1998 Apr; 63(4):403-13. PubMed ID: 9585794
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Blood pressure response to tyramine-enriched meal before and during MAO-inhibition in man: influence of dosage regimen.
    Müller T; Gieschke R; Ziegler WH
    J Neural Transm Suppl; 1988; 26():105-14. PubMed ID: 3162949
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers.
    Yates R; Nairn K; Dixon R; Seaber E
    J Clin Pharmacol; 2002 Nov; 42(11):1237-43. PubMed ID: 12412822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.